The interference of EGFR-TKIs or PD-1/PD-L1 inhibitors on the metabolism of glycerophospholipids or glycerol esters in patients with NSCLC suggests that small-molecule targeted drugs or immunotherapies may also inhibit the malignant proliferation of tumor cells by interfering with cell membrane stability. This evidence concerns the gene EGFR and non-small cell lung carcinoma.